BMC Infectious Diseases

CORRECTION

Open Access

Correction: Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case–control study (SAVALO Study)

Ivan Gentile[1], Agnese Giaccone[2*], Maria Michela Scirocco[1], Francesco Di Brizzi[1], Federica Cuccurullo[1], Maria Silvitelli[1], Luigi Ametrano[1], Francesco Antimo Alfè[1], Daria Pietroluongo[1], Irene Irace[1], Mariarosaria Chiariello[1], Noemi De Felice[1], Simone Severino[1], Giulio Viceconte[1], Nicola Schiano Moriello[1], Alberto Enrico Maraolo[1], Antonio Riccardo Buonomo[1], Riccardo Scotto[1] and Federico II COVID team

Correction: BMC Infect Dis 24, 1434 (2024)
https://doi.org/10.1186/s12879-024-10303-5

Following publication of the original article [1], we were notified of an error in the "Results" section of the Abstract. The following sentence "**1064** patients were included (cases: 423, controls: 1184)" should read "**1607** patients were included (cases: 423, controls: 1184)", as it is later reported in the text (see Results section and Table 1).

The authors would like to clarify that this correction does not affect the overall results, conclusions, or interpretations presented in the article.

The original article has been corrected.

Published online: 29 April 2025

Reference

1. Gentile I, et al. Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study). BMC Infect Dis. 2024;24:1434. https://doi.org/10.1186/s12879-024-10303-5.

The original article can be found online at https://doi.org/10.1186/s12879-024-10303-5.

*Correspondence:
Agnese Giaccone
agnesegiaccone94@gmail.com
[1] Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, Italy
[2] Department of Infectious Diseases, Unit of Geriatric Infectious Diseases, AORN Ospedali Dei Colli, Cotugno Hospital, Naples, Italy